Blood pressure goal achievement with olmesartan medoxomil-based treatment: Additional analysis of the OLMEBEST study

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 723-729

  Barrios, Vivencio ^a   Escobar, Carlos ^a   Calderon, Alberto ^b   Böhm, Michael ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Primary Care Center Rosa de Luxemburgo   (Spain)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Angiotensin II receptor blocker; Goal rates; Hydrochlorothiazide; Hypertension; Olmesartan medoxomil

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 74049152360     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s7003     Document Type: Article

References (24)

1. World Health Organization. Reducing risks, promoting healthy life 2002 [cited 2008 July 30]. http://www.who.int/whr/2002/en/whr02-en.pdf. Accessed August 6, 2009.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275:1571-1576.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
5. Birkenhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens. 1999;17:873-881.
6. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001;19:S49-S56.
7. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig. 2006;26:185-193.
8. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl. 2003;21:S43-S46.
9. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-195.
10. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3:283-291, 318.
11. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87:37C-43C.
12. Püchler K, Laies P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl. 2001;19:s41-s48.
13. Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens. 2005;23:2083-2092.
14. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST study. Clin Drug Investig. 2007;27:545-558.
15. Kjeldsen S, Os I, Høieggen A. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005;5:17-22.
16. Chrysant S, Weber M, Wang A. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17:252-259.
17. Barrios V, Escobar C. Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother. 2008;9:129-136.
18. Rump L, Ambrosioni E, Burnier M, et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens. 2006;20:299-301.
19. Wagstaff AJ. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension. Drugs. 2006;66:1881-1901.
20. Weir MR, Crikelair N, Levy D, et al. Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:103-112.
21. Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168-174.
22. Barrios V, Banegas JR, Ruilope LM, et al. Evolution of blood pressure control in Spain. J Hypertens. 2007;25:1975-1977.
23. Barrios V, Escobar C, Calderon A, et al. Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich). 2007;9:324-329.
24. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-17.